| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | September 21, 1999 |
| PATENT TITLE |
Stabilized thyroid hormone preparations and methods of making same |
| PATENT ABSTRACT |
Disclosed are thyroid hormone preparations useful in pharmaceutical applications. These preparations are disclosed to contain thyroxine drugs in combination with an inorganic salt, a carbohydrate having a molecular weight of greater than 500, and glycine. The preparations are also disclosed to have a free water content less than 4.5% by weight of the preparation. Also provided are compositions containing a reduced carbohydrate, a water soluble polysaccharide, or galactose. The preparations have improved stability wherein they are provided as being stable to the extent that substantially no potency loss is measured when the preparation is stored at 40.degree. C. and 75% relative humidity for 3 months. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | November 14, 1996 |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
We claim: 1. A stable, solid dosage form pharmaceutical preparation suitable for the treatment of thyroid disorders, said preparation comprising: an effective amount of a thyroxine drug; a water soluble glucose polymer; and a partially soluble or insoluble cellulose polymer; said preparation being stable to the extent that substantially no potency loss is measured when the preparation is stored at 40.degree. C. and 75% relative humidity for 6 months. 2. The preparation of claim 1, wherein the preparation is in a unit dose form. 3. The preparation of claim 2, wherein the unit dose form is a tablet. 4. The preparation of claim 3, wherein the tablet additionally includes a lubricant. 5. The preparation of claim 4, wherein the tablet also contains a glidant. 6. The preparation of claim 2, wherein the unit dose form is a capsule. 7. The preparation of claim 1, wherein the capsule also contain a lubricant and a glidant. 8. The preparation of claim 1, wherein the preparation is in the form of a powder. 9. The preparation of claim 1, wherein the preparation is provided in the substantial absence of lactose, glucose, sucrose, or a polyvinylpyrrolidone. 10. The preparation of claim 1 wherein the pH of the preparation is about 7 to 11. 11. The preparation of claim 1 wherein the thyroxine drug is levothyroxine sodium. 12. The preparation of claim 1 having a free water content less than 4.5% by weight of the preparation. 13. The preparation of claim 3 having a free water content less than 4.5% by weight of the preparation. 14. The preparation of claim 10, having a free water content less than 4.5% by weight of the preparation. 15. A stable pharmaceutical preparation comprising: a. an effective amount of a thyroxine drug; b. a water soluble polysaccharide; and c. a partially soluble or insoluble cellulose polymer. 16. The preparation of claim 15 wherein the water soluble polysaccharide is a polysaccharide having a dextrose value of less than 25. 17. The preparation of claim 15 wherein the water soluble polysaccharide is a polysaccharide having a dextrose value of less than 10. 18. The preparation of claim 15 wherein the water soluble polysaccharide comprises a polysaccharide selected from group consisting of maltodextrin, .beta. cyclodextrin, and hydroxypropyl-.beta.-cyclodextrin. 19. The preparation of claim 15, wherein the preparation is a unit dose form. 20. The preparation of claim 16, wherein the preparation is a unit dose form. 21. The preparation of claim 17, wherein the preparation is a unit dose form. 22. The preparation of claim 18, wherein the preparation is a unit dose form. 23. The preparation of claim 19, wherein the unit dose form is a tablet. 24. The preparation of claim 20, wherein the unit dose form is a tablet. 25. The preparation of claim 21, wherein the unit dose form is a tablet. 26. The preparation of claim 22, wherein the unit dose form is a tablet. 27. The preparation of claim 23, wherein the tablet additionally includes a lubricant. 28. The preparation of claim 24, wherein the tablet additionally includes a lubricant. 29. The preparation of claim 25, wherein the tablet additionally includes a lubricant. 30. The preparation of claim 26, wherein the tablet additionally includes a lubricant. 31. The preparation of claim 23, wherein the tablet also contains a glidant. 32. The preparation of claim 24, wherein the tablet also contains a glidant. 33. The preparation of claim 25, wherein the tablet also contains a glidant. 34. The preparation of claim 26, wherein the tablet also contains a glidant. 35. The preparation of claim 27, wherein the tablet also contains a glidant. 36. The preparation of claim 28, wherein the tablet also contains a glidant. 37. The preparation of claim 29, wherein the tablet also contains a glidant. 38. The preparation of claim 30, wherein the tablet also contains a glidant. 39. The preparation of claim 13 wherein the pH of th preparation is about 7 to 11. 40. The preparation of claim 3, 4, 5, 13, 15, 26, 30, 38 or 39 wherein the preparation is provided in the substantial absence of lactose, glucose, sucrose, or a polyvinylpyrrolidone. 41. The preparation of claim 1, 3, 4, 5, 13, 15, 26, 30, 38, or 39 wherein the partially soluble or insoluble polymer comprises microcrystalline cellulose. 42. The preparation of claim 40 wherein the partially soluble or insoluble polymer comprises microcrystalline cellulose. 43. The preparation of claims 3, 4, 5, 13, 15, 26, 30, 38, or 39 wherein the thyroxine drug comprises sodium levothyroxine. 44. The preparation of claims 39 wherein the thyroxine drug comprises sodium levothyroxine. 45. The preparation of claims 40 wherein the thyroxine drug comprises sodium levothyroxine. 46. The preparation of claims 41 wherein the thyroxine drug comprises sodium levothyroxine. 47. The preparation of claims 42 wherein the thyroxine drug comprises sodium levothyroxine. 48. A stable pharmaceutical preparation comprising: a. an effective amount of sodium levothyroxine; b. maltodextrin; and c. microcrystalline cellulose; wherein the combined weight of the maltodextrin and microcrystalline cellulose is from 50% to 99% of the total weight of the preparation. 49. The preparation of claim 48 comprising at least one lubricant selected from the group consisting of magnesium stearate, zinc stearate, sodium stearate fumarate and sodium lauryl sulfate wherein the weight of the lubricant is in the range up to 2% by weight of the preparation. 50. The preparation of claim 49 comprising a glidant selected from the group consisting of colloidal silicon dioxide and talc wherein the weight of the glidant is up to 3% by weight of the preparation. 51. The preparation of claim 50 wherein the preparation is provided in the substantial absence of lactose, glucose, sucrose, or polyvinylpyrrolidone. 52. The preparation of claim 51 comprising a free water content less than 4.5% by weight of the preparation. 53. The preparation of claim 52 wherein the pH of the preparation is about 7 to 11. 54. The preparation of claim 50 comprising about 49.4% by weight maltodextrin, about 49.4% by weight microcrystalline cellulose, about 0.5% by weight sodium lauryl sulfate, about 0.5% by weight magnesium stearate and about 0.02% colloidal silicon dioxide. 55. The preparation of claim 51 comprising about 49.4% by weight maltodextrin, about 49.4% by weight microcrystalline cellulose, about 0.5% by weight sodium lauryl sulfate, about 0.5% by weight magnesium stearate and about 0.02% colloidal silicon dioxide. 56. The preparation of claim 52 comprising about 49.4% by weight maltodextrin, about 49.4% by weight microcrystalline cellulose, about 0.5% by weight sodium lauryl sulfate, about 0.5% by weight magnesium stearate and about 0.02% colloidal silicon dioxide. 57. The preparation of claim 53 comprising about 49.4% by weight maltodextrin, about 49.4% by weight microcrystalline cellulose, about 0.5% by weight sodium lauryl sulfate, about 0.5% by weight magnesium stearate and about 0.02% colloidal silicon dioxide. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION | This data is not available for free |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |